13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

GSK PLC ADR GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • It operates through Commercial Operations and Total R&D segments.
  • It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps.
  • Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
  • It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 3 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 13.45 FCF 8.22% Buyback 1.13%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Bridgewater Associates Ray Dalio 0.2% $38.6M 2026-03-31
Kahn Brothers Group 1.6% $8.9M 2026-03-31
Tweedy, Browne Company 0.4% $4.5M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 0 Last 3 13F filing periods
Net reducers 3 Last 3 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $0 Estimated from net added shares
Reduction amount $63.4M Estimated from net reduced shares
Net share change / base shares -55.0% -1,149,352 / 2,090,785
Bridgewater Associates Ray Dalio 3 filing periods
13F 2025-09-30 Filed 2025-11-13
Minor increase Shares 4.3% 13F value change +$8.9M
13F 2025-12-31 Filed 2026-02-13
Minor increase Shares 1.1% 13F value change +$9.0M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -50.7% 13F value change -$30.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 1,344,042 Last 3 periods -645,376 (-48.0%) Total shares 698,666 Value $38.6M
Kahn Brothers Group 3 filing periods
13F 2025-09-30 Filed 2025-11-12
Major reduction Shares -60.5% 13F value change -$14.1M
13F 2025-12-31 Filed 2026-02-12
Major reduction Shares -31.5% 13F value change -$2.5M
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -9.9% 13F value change +$121,345
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 659,872 Last 3 periods -498,890 (-75.6%) Total shares 160,982 Value $8.9M
Tweedy, Browne Company 3 filing periods
13F 2025-09-30 Filed 2025-11-20
Minor reduction Shares -5.3% 13F value change +$213,762
13F 2025-12-31 Filed 2026-02-03
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-06
Minor reduction Shares -0.6% 13F value change +$480,517
Settlement As of 13F 2026-03-31 · Filed 2026-05-06
Base shares 86,871 Last 3 periods -5,086 (-5.9%) Total shares 81,785 Value $4.5M

Recent mentions

No public mentions.